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Abstract
Background and Purpose: Coronavirus disease 2019 (CO
VID-19) has an increased propensity for systemic hypercoagulability and thromboembolism. An association with cerebrovascular diseases, especially cerebral venous thrombosis
(CVT), has been reported among these patients. The objective of the present study was to identify risk factors for CVT
as well as its presentation and outcome in COVID-19 patients. Methods: This is a multicenter and multinational observational study. Ten centers in 4 countries (Pakistan, Egypt,
Singapore, and the United Arab Emirates) participated in this
study. The study included patients (aged >18 years) with
symptomatic CVT and recent COVID-19 infection. Results:
Twenty patients (70% men) were included. Their mean age
was 42.4 years, with a male-to-female ratio of 2.3:1. Headache (85%) and seizures (65%) were the common presenting

symptoms, with a mean admission Glasgow Coma Scale
(GCS) score of 13. CVT was the presenting feature in 13 cases
(65%), while 7 patients (35%) developed CVT while being
treated for COVID-19 infection. Respiratory symptoms were
absent in 45% of the patients. The most common imaging
finding was infarction (65%), followed by hemorrhage (20%).
The superior sagittal sinus (65%) was the most common site
of thrombosis. Acute inflammatory markers were raised, including elevated serum D-dimer (87.5%), erythrocyte sedimentation rate (69%), and C-reactive protein (47%) levels.
Homocysteine was elevated in half of the tested cases. The
mortality rate was 20% (4 patients). A good functional outcome was seen in the surviving patients, with a mean modified Rankin Scale score at discharge of 1.3. Nine patients
(45%) had a modified Rankin Scale score of 0–1 at discharge.
Conclusion: COVID-19-related CVT is more common among
males at older ages when compared to previously reported
non-COVID-19-related CVT cases. CVT should be suspected
in COVID-19 patients presenting with headache or seizures.
Mortality is high, but functional neurological outcome is
good among survivors.
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Introduction

Results

Coronavirus disease 2019 (COVID-19) is a novel infection caused by the SARS-CoV-2 coronavirus, resulting
in severe acute respiratory syndrome (SARS). An increased propensity for systemic hypercoagulability and
thromboembolism has been reported among COVID-19
patients [1–3]. In one study, thrombotic complications
were reported in approximately one-third of the critically
ill COVID-19 patients [1]. An increase in cerebrovascular
diseases (1–6%) has also been reported among these patients [4]. Published data on cerebral venous thrombosis
(CVT) among COVID-19 patients are limited. Hughes et
al. [5] published the first case of CVT in a COVID-19 patient in April 2020. To the best of our knowledge, only 12
CVT cases among COVID-19 patients have been reported in the literature [6]. All these cases are presented in
single-center case reports. The purpose of this study was
to identify the risk factors for CVT as well as its presentation and outcome in COVID-19 patients in a multinational, multicenter setting using a prespecified data collection tool.
Subjects and Methods
We conducted a multicenter observational study. Ten centers in 4 countries (Pakistan, Egypt, Singapore, and the United
Arab Emirates) participated in the study. All 10 centers are tertiary care hospitals with full-time neurologists and availability of
diagnostic modalities for the diagnosis of CVT as well as CO
VID-19. Data were collected on a prespecified questionnaire.
They were collected retrospectively from COVID-19 registries
and hospital medical records. All patients fulfilling the inclusion
criteria were included. One male patient with recent head trauma with COVID-19 and CVT was excluded. Patients aged 18
years or above with recent COVID-19 infection, confirmed either by reverse transcriptase-polymerase chain reaction assay
of a nasopharyngeal swab or serum antibody testing for CO
VID-19, were included. Diagnosis of CVT was confirmed by at
least one of the following imaging studies according to the established criteria: magnetic resonance (MR) imaging, MR venography (MRV), computed tomography (CT), CT venography,
or cerebral venography. Patients with recent trauma and patients already receiving anticoagulation were excluded. The data
included risk factors, clinical features, laboratory findings, imaging findings, COVID-19-related information, and data on
management and outcome for all patients enrolled in the study.
The patients were identified through the medical record system
of the hospitals and COVID-19 registries at the various centers.
Data are presented as frequencies and correlations.
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A total of 20 cases were included (Table 1) from 4
countries (13 from Pakistan, 4 from Egypt, 2 from Singapore, and 1 from the United Arab Emirates). Eighteen
cases (90%) tested positive for SARS-CoV-2 by reverse
transcriptase-polymerase chain reaction assay of a nasopharyngeal swab, while 2 cases (10%) tested positive for
COVID-19 antibodies. Out of 20 subjects, 14 were male
(70%). The average age was 42.4 years. In 19 cases (95%),
the diagnosis of CVT was confirmed by MRV and/or CT
venography, while 1 patient had a noncontrast CT scan
suggestive of superior sagittal sinus thrombosis.
Clinical Features, Risk Factors, and Comorbid
Conditions
Headache (85%, n = 17) and seizures (65%, n = 13)
were the most common neurological features. Headache
was of 3–7 days in duration in 76% of the cases. Seizures
were of generalized onset in 10 cases (77%) and focal onset in 3 cases (23%). The mean Glasgow Coma Scale
(GCS) score on admission was 13. Cigarette-smoking
(45%, n = 9) and hypertension (35%, n = 7) were the most
common vascular risk factors present. One female was on
oral contraceptives despite a previous history of CVT.
One female had a history of deep venous thrombosis, and
1 male had polycythemia. Four cases were dehydrated
(20%) on presentation.
Relationship to COVID-19 Infection
CVT was the presenting feature in 13 (65%) of cases,
whereas 7 (35%) developed CVT while being treated for
COVID-19 infection. Two patients with positive CO
VID-19 antibodies likely presented with late-stage COVID-19. Nine cases (45%) did not have respiratory symptoms at the time of diagnosis of CVT. In 5 patients (25%),
CVT was the sole presentation of COVID-19 (absence of
fever and respiratory symptoms).
Laboratory Workup and Imaging Findings
Important laboratory findings included elevated levels
of serum D-dimer (87.5%), erythrocyte sedimentation
rate (69%), and leukocytosis (72%). Homocysteine was
elevated in 50% of the tested cases. Two out of 9 patients
had positive lupus anticoagulant (LA). The most common imaging finding was infarction (65%, n = 13), more
than one-third of which were hemorrhagic infarcts (38%,
n = 5), followed by hemorrhage only in 4 patients (20%).
The superior sagittal sinus was the most common site of
thrombosis (65%, n = 13) using all modalities.
Hameed et al.

COVID-19 and Cerebral Venous
Thrombosis

Cerebrovasc Dis Extra 2021;11:55–60
DOI: 10.1159/000516641

57

Pakistan

Pakistan

Egypt

Egypt

Egypt

Egypt

13

14

15

16

17

Pakistan

8

12

Pakistan

7

Pakistan

Pakistan

6

11

Pakistan

5

Pakistan

Pakistan

4

10

Pakistan

3

Pakistan

Pakistan

2

9

Pakistan

Country

1

No.

tient

Pa

43/M

42/M

33/F

36/F

43/F

32/M

36/F

54/F

54/M

41/F

29/M

44/M

45/M

80/M

52/M

36/M

34/F

years

A/G,

CS

CS

Migraine, CS

Obesity,
gestational HTN

HTN

CS

DM, HTN, CAD

DM, HTN, CS

DM, HTN, CS

HTN

–

CS

DM, CS

–

–

HTN, CS

–

PMH

Headache, blurred vision

Headache, seizures, altered
mentation

Headache, seizures, hemiparesis

Headache, seizures

Headache, seizures, papilledema
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Table 1. Patients with COVID-19 and CVT
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Infarction (TS + sigmoid sinus
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–
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–
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–

–
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2
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1
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1

2

0

1

4

2

2
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Abs, antibodies; A/g, age and gender; CS, cigarette-smoking; CVST, cerebral venous sinus thrombosis; CVT, cerebral venous thrombosis; DM, diabetes mellitus; EVD, extraventricular drain; F, female; Inc., increased; IJV,
internal jugular vein; HTN, hypertension; LMWH, low-molecular-weight heparin; Lt., left; M, male; mRS, modified Rankin Scale; N/A, not available; N/V, nausea and vomiting; Neg., negative; NPS, nasopharyngeal swab; PCT,
polycythemia; PMH, past medical history; Pos., positive; Rt., right; SSS, superior sagittal sinus; TS, transverse sinus; UAE, United Arab Emirates; UFH, unfractionated heparin; URTI, upper respiratory tract infection; VP shunt,
ventriculoperitoneal shunt.
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Management and Outcome
Eighteen cases (90%) received systemic anticoagulation treatment, with the majority of the patients receiving
low-molecular-weight heparin (56%, n = 10) and unfractionated heparin (22%, n = 4) for initial anticoagulation.
Besides anticoagulation, thrombectomy, intravenous
thrombolysis, ventriculoperitoneal shunt, and decompressive craniectomy with extraventricular drain placement were performed on 1 patient each.
Fifteen cases (75%) were discharged home with an improving condition, 4 cases (20%) died, and 1 case (5%)
was referred to another hospital for rehabilitation. All 4
patients who died had a low GCS score (8–10) at admission. The discharged cases had an average modified
Rankin Scale score of 1.3. Patients with good functional
outcome had no or mild respiratory symptoms, a high
GCS score (13–15) at admission, and/or a normal brain
parenchyma on imaging.
Discussion

This is the first and the largest multicenter and multinational study of CVT in COVID-19 patients. This patient population differs in many aspects from previously
reported non-COVID-19 CVT patients, where CVT is
more common in the third decade of life with a female
predominance [7–9]. In this study, males were twice as
frequently affected, with an average age of 42.4 years. Although the incidence of CVT increases during the puerperal period and is associated with oral contraceptive pill
(OCP) use (11–54%) [7–11], in our study only 1 patient
was in the puerperal period (3 days after cesarean section)
and 1 patient had a history of OCP use.
A hypercoagulable state is an important and wellknown risk factor for CVT [10–14]. In a study among
critically ill COVID-19 patients (n = 184), 31% of the patients developed thrombotic complications, with pulmonary embolism topping the list [1]. Similarly, another
study reported a high frequency of venous thrombo
embolism (21%) among COVID-19 patients [2]. An increased LA positivity is reported in acute COVID-19 infections [3, 12, 13]. These LA antibodies are presumed to
increase the risk of thromboembolism but are transiently
elevated in the acute viral setting [14]. A prolonged activated partial thromboplastin time in the presence of LA
does not increase the bleeding risk, and these patients
may receive anticoagulation if clinically indicated [15]. In
our study, 9 cases (45%) also did not have respiratory
symptoms. Tan et al. [12] reported an absence of respiraHameed et al.

tory symptoms in 24% of their COVID-19 patients with
acute ischemic stroke.
SARS-CoV-2, responsible for COVID-19 infection, is
well known to bind angiotensin-converting enzyme
(ACE) 2 receptors, which are variably present in the arterial and venous vascular endothelium. Autopsy studies
have revealed that ACE2 receptors are more abundant in
the arterial endothelium than in the venular endothelium
[16]. This expression of ACE receptors probably explains
the high frequency of arterial stroke. COVID-19 not only
causes direct vascular damage but may also create an intense inflammatory reaction affecting hemostasis and the
coagulation cascade. COVID-19-associated arterial
stroke predominantly affects younger males with vascular
risk factors and mostly presents as large vessel stroke [17].
These findings may suggest a common pathway for both
COVID-19-associated CVT and arterial stroke.
The main limitations of our study are selection bias,
the absence of a control sample, the absence of prothrombotic workup, limited neurological examination, and the
inability to examine the influence of confounding variables on outcomes. The current number of CVT cases is
probably an underestimation. COVID-19 testing may be
included as standard workup among all CVT patients,
including those who have no throat or respiratory symptoms. All COVID-19-positive patients with headache and
neurological symptoms should be evaluated for CVT.
Early diagnosis by MRI and MRV and anticoagulation for
high-risk populations (with a history of venous thromboembolism, a postpartum state, or use of OCPs) may lead
to improved outcomes.
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